Chemotherapy with MOPP versus hybrid MOPP /EVAP in advanced Hodgkin's disease

Submission date	Recruitment status	Prospectively registered
01/07/2001	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
01/07/2001	Completed	Results
Last Edited	Condition category	[] Individual participant data
21/01/2019	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

Protocol serial number H14

Study information

Scientific Title

Chemotherapy with MOPP versus hybrid MOPP/EVAP in advanced Hodgkin's disease

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lymphoma (Hodgkin's)

Interventions

Patients are randomised to one of two chemotherapy regimens:

- 1. MOPP Regimen: Multi-drug chemotherapy with mustine, vincristine (Oncovin), procarbazine and prednisolone (MOPP) repeated every 4 weeks for a minimum of four courses.
- 2. MOPP/EVAP Regimen: Multi-drug chemotherapy with MOPP alternating every 2 weeks with etoposide, vinblastine, adriamycin and prednisolone (EVAP) for a minimum of eight courses of chemotherapy (ie four courses each of MOPP and EVAP).

Intervention Type

Drug

Phase

Not Applicable

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s))

Not provided at time of registration

Completion date

01/10/1993

Eligibility

Key inclusion criteria

- 1. Hodgkin's lymphoma stage IIB, III or IV
- 2. Staging to include adequate documentation of systemic symptoms, and Computed Tomography (CT) scan (except stage IV)
- 3. Local hisopathological review of diagnosis
- 4. No medical contraindications to treatment protocols

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1989

Date of final enrolment

01/10/1993

Locations

Countries of recruitment

United Kingdom

England

Study participating centre MRC Clinical Trials Unit

London United Kingdom NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

https://ror.org/054225q67

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes